Small cell lung cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?

Paul A. Bunn; John D. Minna; Alexander Augustyn; Adi F. Gazdar; Youcef Ouadah; Mark A. Krasnow; Anton Berns; Elisabeth Brambilla; Natasha Rekhtman; Pierre P. Massion; Matthew Niederst; Martin Peifer; Jun Yokota; Ramaswamy Govindan; John T. Poirier; Lauren A. Byers; Murry W. Wynes; David G. McFadden; David MacPherson; Christine L. Hann; Anna F. Farago; Caroline Dive; Beverly A. Teicher; Craig D. Peacock; Jane E. Johnson; Melanie H. Cobb; Hans Guido Wendel; David Spigel; Julien Sage; Ping Yang; M. Catherine Pietanza; Lee M. Krug; John Heymach; Peter Ujhazy; Caicun Zhou; Koichi Goto; Afshin Dowlati; Camilla Laulund Christensen; Keunchil Park; Lawrence H. Einhorn; Martin J. Edelman; Giuseppe Giaccone; David E. Gerber; Ravi Salgia; Taofeek Owonikoko; Shakun Malik; Niki Karachaliou; David R. Gandara; Ben J. Slotman; Fiona Blackhall; Glenwood Goss; Roman Thomas; Charles M. Rudin; Fred R. Hirsch

doi:10.1016/j.jtho.2016.01.012

Small cell lung cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?

Paul A. Bunn, John D. Minna, Alexander Augustyn, Adi F. Gazdar, Youcef Ouadah, Mark A. Krasnow, Anton Berns, Elisabeth Brambilla, Natasha Rekhtman, Pierre P. Massion, Matthew Niederst, Martin Peifer, Jun Yokota, Ramaswamy Govindan, John T. Poirier, Lauren A. Byers, Murry W. Wynes, David G. McFadden, David MacPherson, Christine L. HannAnna F. Farago, Caroline Dive, Beverly A. Teicher, Craig D. Peacock, Jane E. Johnson, Melanie H. Cobb, Hans Guido Wendel, David Spigel, Julien Sage, Ping Yang, M. Catherine Pietanza, Lee M. Krug, John Heymach, Peter Ujhazy, Caicun Zhou, Koichi Goto, Afshin Dowlati, Camilla Laulund Christensen, Keunchil Park, Lawrence H. Einhorn, Martin J. Edelman, Giuseppe Giaccone, David E. Gerber, Ravi Salgia, Taofeek Owonikoko, Shakun Malik, Niki Karachaliou, David R. Gandara, Ben J. Slotman, Fiona Blackhall, Glenwood Goss, Roman Thomas, Charles M. Rudin, Fred R. Hirsch

Research output: Contribution to journal › Review article › peer-review

140 Scopus citations

Original language	English
Pages (from-to)	453-474
Number of pages	22
Journal	Journal of Thoracic Oncology
Volume	11
Issue number	4
DOIs	https://doi.org/10.1016/j.jtho.2016.01.012
State	Published - 2016

Keywords

Gene mutations
Immunotherapy
Neuroendocrine
Small cell lung cancer
Therapy

Access to Document

10.1016/j.jtho.2016.01.012

Cite this

Bunn, P. A., Minna, J. D., Augustyn, A., Gazdar, A. F., Ouadah, Y., Krasnow, M. A., Berns, A., Brambilla, E., Rekhtman, N., Massion, P. P., Niederst, M., Peifer, M., Yokota, J., Govindan, R., Poirier, J. T., Byers, L. A., Wynes, M. W., McFadden, D. G., MacPherson, D., ... Hirsch, F. R. (2016). Small cell lung cancer: Can recent advances in biology and molecular biology be translated into improved outcomes? Journal of Thoracic Oncology, 11(4), 453-474. https://doi.org/10.1016/j.jtho.2016.01.012

@article{5f62971581bc44db84270370e5b92b74,

title = "Small cell lung cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?",

keywords = "Gene mutations, Immunotherapy, Neuroendocrine, Small cell lung cancer, Therapy",

author = "Bunn, {Paul A.} and Minna, {John D.} and Alexander Augustyn and Gazdar, {Adi F.} and Youcef Ouadah and Krasnow, {Mark A.} and Anton Berns and Elisabeth Brambilla and Natasha Rekhtman and Massion, {Pierre P.} and Matthew Niederst and Martin Peifer and Jun Yokota and Ramaswamy Govindan and Poirier, {John T.} and Byers, {Lauren A.} and Wynes, {Murry W.} and McFadden, {David G.} and David MacPherson and Hann, {Christine L.} and Farago, {Anna F.} and Caroline Dive and Teicher, {Beverly A.} and Peacock, {Craig D.} and Johnson, {Jane E.} and Cobb, {Melanie H.} and Wendel, {Hans Guido} and David Spigel and Julien Sage and Ping Yang and Pietanza, {M. Catherine} and Krug, {Lee M.} and John Heymach and Peter Ujhazy and Caicun Zhou and Koichi Goto and Afshin Dowlati and Christensen, {Camilla Laulund} and Keunchil Park and Einhorn, {Lawrence H.} and Edelman, {Martin J.} and Giuseppe Giaccone and Gerber, {David E.} and Ravi Salgia and Taofeek Owonikoko and Shakun Malik and Niki Karachaliou and Gandara, {David R.} and Slotman, {Ben J.} and Fiona Blackhall and Glenwood Goss and Roman Thomas and Rudin, {Charles M.} and Hirsch, {Fred R.}",

note = "Funding Information: Disclosure: Dr. Bunn has received consulting fees from AstraZeneca, BMS, Clovis, Daiichi, Genentech, Merck, Novartis, Sanofi, Lilly, Merck-Serono, and Pfizer, and his institution has received grants from the National Cancer Institute and Eisai. Dr. Minna reports grants from the National Cancer Institute and the Cancer Prevention and Research Institute of Texas, personal fees from the National Institutes of Health and Genentech, and laboratory research funding from SCLC cell line licensing fees from the University of Texas Southwestern Medical Center during the conduct of the study, as well as grants from the National Cancer Institute, grants from the Cancer Prevention and Research Institute of Texas, personal fees from the National Institutes of Health and Genentech, and laboratory research funding from SCLC cell line licensing fees from University of Texas Southwestern Medical Center outside the submitted work. Dr. Niederst reports personal fees from Boehringer Ingelheim during the conduct of the study as well as personal fees from Boerhinger Ingelheim outside the submitted work. Dr. Peifer reports personal fees from NEO New Oncology AG, is one of its shareholders, and receives personal fees for serving as a scientific advisor to it outside the submitted work. Dr. Govindan reports personal fees from Celgene, Bayer, Roche, Clovis, Boehringer Ingelheim, Helsinn, Genentech, AbbVie, GSK, Novartis, Genecentric, Merck, and Pfizer outside the submitted work. Dr. Byers serves on consulting/advisory boards for BioMarin, AstraZeneca, and AbbVie. Dr. Farago reports personal fees from Intervention Insights outside the submitted work. Dr. Dive reports personal fees from Intervention Insights outside the submitted work. Dr. Peacock reports receiving grants from Flight Attendant Medical Research Institute (FAMRI) and nonfinancial support from Novartis during the conduct of the study. Dr. Spigel is a noncompensated advisor to BMS, Genentech/Roche, Novartis, and Pfizer, and he also serves on the Data Safety Monitoring Board for Merck. Dr. Pietanza reports personal fees from Genentech, CelGene Corp, Abbvie, and Clovis Oncology; grants and personal fees from Novartis and Bristol Myers Squibb; and grants from Stemcentrx, Inc., and OncoMed Pharmaceuticals, Inc., outside the submitted work. Dr. Krug reports grants from Bristol-Myers Squibb during the conduct of the study and is also a current employee of Bristol-Myers Squibb. Dr. Heymach reports grants from AstraZeneca, GlaxoSmithKline, and Bayer during the conduct of the study and grants from Genentech outside the submitted work, and he serves on advisory boards of AstraZeneca, Novartis, GlaxoSmithKline, Lilly, Boerhinger Ingelheim, Synta, and Exelixis. Dr. Goto reports grants from MSD K.K., grants and personal fees from AstraZeneca K.K., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim CO., Ltd, and Ono Pharmaceutical Co., Ltd.; grants from Quintiles Inc., GlaxoSmithKline K.K, and OxOnc; grants and personal fees from Pfizer Inc., Kyowa Hakko Kirin Co., Ltd, and Eli Lilly Japan K.K; personal fees from Yakult Honsha Co., Ltd.; grants from Sumitomo Dainippon Pharma Co., Ltd., and Takeda Pharmaceutical Co., Ltd.; grants and personal fees from Novartis Pharma K.K. and grants and personal fees from DAIICHI SANKYO Co., Ltd.; grants from Astellas Pharma Inc., Eisai Co., Ltd., Amgen Astellas BioPharma K.K.; and personal fees from Bristol-Myers Squibb Co. outside the submitted work. Dr. Park reports grants from Astra Zeneca and fees from Astra Zeneca for serving as an advisor, as well as fees for serving as an advisor to Astellas Boehringer Ingelheim, Clovis, Eli Lilly, Hanmi, KHK, ONO, Novartis, and Roche outside the submitted work. Dr. Edelman, MD reports personal fees from Andarix Pharmaceuticals during the conduct of this study, as well as grants from BMS, Oncomed, Genentech, Novartis, Peregrine, Heat Biologics, Adaptimmune, and Endocyte outside the submitted work. Dr. Slotman reports grants and personal fees from Varian Medical Systems, as well as grants and personal fees from BrainLAB AG outside the submitted work. Dr. Thomas reports grants from German Cancer Aid, BMBF e:Med, and Deutsche Forschungsgemeinschaft during the conduct of the study; he is the founder and a shareholder of New Oncology AG; and he has received personal fees from Sanofi-Aventis, grants and personal fees from Merck, personal fees from Roche and Lilly, personal fees from Boehringer Ingelheim, grants and personal fees from AstraZeneca, personal fees from Atlas-Bioloabs and Daiichi-Sankyo, personal fees from MSD and Puma, and grants from EOS outside the submitted work. Dr. Rudin reports consulting fees from Abbvie, Boehringer Ingelheim, Celgene, GSK, and Merck, and a grant from Biomarin outside the submitted work. Dr. Hirsch is the chief executive director of the International Association for the Study of Lung Cancer. The remaining authors declare no conflict of interest. ",

year = "2016",

doi = "10.1016/j.jtho.2016.01.012",

language = "English",

volume = "11",

pages = "453--474",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

number = "4",

}

Bunn, PA, Minna, JD, Augustyn, A, Gazdar, AF, Ouadah, Y, Krasnow, MA, Berns, A, Brambilla, E, Rekhtman, N, Massion, PP, Niederst, M, Peifer, M, Yokota, J, Govindan, R, Poirier, JT, Byers, LA, Wynes, MW, McFadden, DG, MacPherson, D, Hann, CL, Farago, AF, Dive, C, Teicher, BA, Peacock, CD, Johnson, JE, Cobb, MH, Wendel, HG, Spigel, D, Sage, J, Yang, P, Pietanza, MC, Krug, LM, Heymach, J, Ujhazy, P, Zhou, C, Goto, K, Dowlati, A, Christensen, CL, Park, K, Einhorn, LH, Edelman, MJ, Giaccone, G, Gerber, DE, Salgia, R, Owonikoko, T, Malik, S, Karachaliou, N, Gandara, DR, Slotman, BJ, Blackhall, F, Goss, G, Thomas, R, Rudin, CM & Hirsch, FR 2016, 'Small cell lung cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?', Journal of Thoracic Oncology, vol. 11, no. 4, pp. 453-474. https://doi.org/10.1016/j.jtho.2016.01.012

TY - JOUR

T1 - Small cell lung cancer

T2 - Can recent advances in biology and molecular biology be translated into improved outcomes?

AU - Bunn, Paul A.

AU - Minna, John D.

AU - Augustyn, Alexander

AU - Gazdar, Adi F.

AU - Ouadah, Youcef

AU - Krasnow, Mark A.

AU - Berns, Anton

AU - Brambilla, Elisabeth

AU - Rekhtman, Natasha

AU - Massion, Pierre P.

AU - Niederst, Matthew

AU - Peifer, Martin

AU - Yokota, Jun

AU - Govindan, Ramaswamy

AU - Poirier, John T.

AU - Byers, Lauren A.

AU - Wynes, Murry W.

AU - McFadden, David G.

AU - MacPherson, David

AU - Hann, Christine L.

AU - Farago, Anna F.

AU - Dive, Caroline

AU - Teicher, Beverly A.

AU - Peacock, Craig D.

AU - Johnson, Jane E.

AU - Cobb, Melanie H.

AU - Wendel, Hans Guido

AU - Spigel, David

AU - Sage, Julien

AU - Yang, Ping

AU - Pietanza, M. Catherine

AU - Krug, Lee M.

AU - Heymach, John

AU - Ujhazy, Peter

AU - Zhou, Caicun

AU - Goto, Koichi

AU - Dowlati, Afshin

AU - Christensen, Camilla Laulund

AU - Park, Keunchil

AU - Einhorn, Lawrence H.

AU - Edelman, Martin J.

AU - Giaccone, Giuseppe

AU - Gerber, David E.

AU - Salgia, Ravi

AU - Owonikoko, Taofeek

AU - Malik, Shakun

AU - Karachaliou, Niki

AU - Gandara, David R.

AU - Slotman, Ben J.

AU - Blackhall, Fiona

AU - Goss, Glenwood

AU - Thomas, Roman

AU - Rudin, Charles M.

AU - Hirsch, Fred R.

N1 - Funding Information: Disclosure: Dr. Bunn has received consulting fees from AstraZeneca, BMS, Clovis, Daiichi, Genentech, Merck, Novartis, Sanofi, Lilly, Merck-Serono, and Pfizer, and his institution has received grants from the National Cancer Institute and Eisai. Dr. Minna reports grants from the National Cancer Institute and the Cancer Prevention and Research Institute of Texas, personal fees from the National Institutes of Health and Genentech, and laboratory research funding from SCLC cell line licensing fees from the University of Texas Southwestern Medical Center during the conduct of the study, as well as grants from the National Cancer Institute, grants from the Cancer Prevention and Research Institute of Texas, personal fees from the National Institutes of Health and Genentech, and laboratory research funding from SCLC cell line licensing fees from University of Texas Southwestern Medical Center outside the submitted work. Dr. Niederst reports personal fees from Boehringer Ingelheim during the conduct of the study as well as personal fees from Boerhinger Ingelheim outside the submitted work. Dr. Peifer reports personal fees from NEO New Oncology AG, is one of its shareholders, and receives personal fees for serving as a scientific advisor to it outside the submitted work. Dr. Govindan reports personal fees from Celgene, Bayer, Roche, Clovis, Boehringer Ingelheim, Helsinn, Genentech, AbbVie, GSK, Novartis, Genecentric, Merck, and Pfizer outside the submitted work. Dr. Byers serves on consulting/advisory boards for BioMarin, AstraZeneca, and AbbVie. Dr. Farago reports personal fees from Intervention Insights outside the submitted work. Dr. Dive reports personal fees from Intervention Insights outside the submitted work. Dr. Peacock reports receiving grants from Flight Attendant Medical Research Institute (FAMRI) and nonfinancial support from Novartis during the conduct of the study. Dr. Spigel is a noncompensated advisor to BMS, Genentech/Roche, Novartis, and Pfizer, and he also serves on the Data Safety Monitoring Board for Merck. Dr. Pietanza reports personal fees from Genentech, CelGene Corp, Abbvie, and Clovis Oncology; grants and personal fees from Novartis and Bristol Myers Squibb; and grants from Stemcentrx, Inc., and OncoMed Pharmaceuticals, Inc., outside the submitted work. Dr. Krug reports grants from Bristol-Myers Squibb during the conduct of the study and is also a current employee of Bristol-Myers Squibb. Dr. Heymach reports grants from AstraZeneca, GlaxoSmithKline, and Bayer during the conduct of the study and grants from Genentech outside the submitted work, and he serves on advisory boards of AstraZeneca, Novartis, GlaxoSmithKline, Lilly, Boerhinger Ingelheim, Synta, and Exelixis. Dr. Goto reports grants from MSD K.K., grants and personal fees from AstraZeneca K.K., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim CO., Ltd, and Ono Pharmaceutical Co., Ltd.; grants from Quintiles Inc., GlaxoSmithKline K.K, and OxOnc; grants and personal fees from Pfizer Inc., Kyowa Hakko Kirin Co., Ltd, and Eli Lilly Japan K.K; personal fees from Yakult Honsha Co., Ltd.; grants from Sumitomo Dainippon Pharma Co., Ltd., and Takeda Pharmaceutical Co., Ltd.; grants and personal fees from Novartis Pharma K.K. and grants and personal fees from DAIICHI SANKYO Co., Ltd.; grants from Astellas Pharma Inc., Eisai Co., Ltd., Amgen Astellas BioPharma K.K.; and personal fees from Bristol-Myers Squibb Co. outside the submitted work. Dr. Park reports grants from Astra Zeneca and fees from Astra Zeneca for serving as an advisor, as well as fees for serving as an advisor to Astellas Boehringer Ingelheim, Clovis, Eli Lilly, Hanmi, KHK, ONO, Novartis, and Roche outside the submitted work. Dr. Edelman, MD reports personal fees from Andarix Pharmaceuticals during the conduct of this study, as well as grants from BMS, Oncomed, Genentech, Novartis, Peregrine, Heat Biologics, Adaptimmune, and Endocyte outside the submitted work. Dr. Slotman reports grants and personal fees from Varian Medical Systems, as well as grants and personal fees from BrainLAB AG outside the submitted work. Dr. Thomas reports grants from German Cancer Aid, BMBF e:Med, and Deutsche Forschungsgemeinschaft during the conduct of the study; he is the founder and a shareholder of New Oncology AG; and he has received personal fees from Sanofi-Aventis, grants and personal fees from Merck, personal fees from Roche and Lilly, personal fees from Boehringer Ingelheim, grants and personal fees from AstraZeneca, personal fees from Atlas-Bioloabs and Daiichi-Sankyo, personal fees from MSD and Puma, and grants from EOS outside the submitted work. Dr. Rudin reports consulting fees from Abbvie, Boehringer Ingelheim, Celgene, GSK, and Merck, and a grant from Biomarin outside the submitted work. Dr. Hirsch is the chief executive director of the International Association for the Study of Lung Cancer. The remaining authors declare no conflict of interest.

PY - 2016

Y1 - 2016

KW - Gene mutations

KW - Immunotherapy

KW - Neuroendocrine

KW - Small cell lung cancer

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84962812153&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2016.01.012

DO - 10.1016/j.jtho.2016.01.012

M3 - Review article

C2 - 26829312

AN - SCOPUS:84962812153

SN - 1556-0864

VL - 11

SP - 453

EP - 474

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 4

ER -

Small cell lung cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?

Keywords

Access to Document

Other files and links

Cite this